151 related articles for article (PubMed ID: 36587740)
1. Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 Years.
Webster JA; Reed M; Tsai HL; Ambinder A; Jain T; Dezern AE; Levis MJ; Showel MM; Prince GT; Hourigan CS; Gladstone DE; Bolanos-Meade J; Gondek LP; Ghiaur G; Dalton WB; Paul S; Fuchs EJ; Gocke CB; Ali SA; Huff CA; Borrello IM; Swinnen L; Wagner-Johnston N; Ambinder RF; Luznik L; Gojo I; Smith BD; Varadhan R; Jones RJ; Imus PH
Transplant Cell Ther; 2023 Mar; 29(3):182.e1-182.e8. PubMed ID: 36587740
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide.
Webster JA; Luznik L; Tsai HL; Imus PH; DeZern AE; Pratz KW; Levis MJ; Gojo I; Showel MM; Prince G; Bolaños-Meade J; Gondek LP; Ghiaur G; Dalton WB; Jain T; Fuchs EJ; Gladstone DE; Gocke CB; Ali SA; Huff CA; Borrello IM; Swinnen L; Wagner-Johnston N; Ambinder RF; Jones RJ; Smith BD
Blood Adv; 2020 Oct; 4(20):5078-5088. PubMed ID: 33080006
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma.
Ghosh N; Ye X; Tsai HL; Bolaños-Meade J; Fuchs EJ; Luznik L; Swinnen LJ; Gladstone DE; Ambinder RF; Varadhan R; Shanbhag S; Brodsky RA; Borrello IM; Jones RJ; Matsui W; Huff CA
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1903-1909. PubMed ID: 28711728
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source.
Sterling CH; Hughes MS; Tsai HL; Yarkony K; Fuchs EJ; Swinnen LJ; Paul S; Bolaños-Meade J; Luznik L; Imus PH; Ali SA; Jain T; Ambinder A; DeZern A; Huff CA; Gocke CB; Varadhan R; Wagner-Johnston N; Jones RJ; Ambinder RF
Transplant Cell Ther; 2023 Apr; 29(4):267.e1-267.e5. PubMed ID: 36549386
[TBL] [Abstract][Full Text] [Related]
5. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Houhou M; Aljurf M; Mousavi A; Hamladji RM; Al Zahrani M; Bondarenko S; Arat M; Angelucci E; Koc Y; Gülbas Z; Sica S; Bourhis JH; Canaani J; Brissot E; Giebel S; Mohty M
J Hematol Oncol; 2021 Apr; 14(1):53. PubMed ID: 33794963
[TBL] [Abstract][Full Text] [Related]
6. Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Giebel S; Labopin M; Salmenniemi U; Socié G; Bondarenko S; Blaise D; Kröger N; Vydra J; Grassi A; Bonifazi F; Czerw T; Anagnostopoulos A; Lioure B; Ruggeri A; Savani B; Spyridonidis A; Sanz J; Peric Z; Nagler A; Ciceri F; Mohty M
Cancer; 2023 Dec; 129(23):3735-3745. PubMed ID: 37658621
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) in second complete remission (CR2) transplanted from unrelated donors with post-transplant cyclophosphamide (PTCy). A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Swoboda R; Kulagin A; Labussière-Wallet H; Rovira M; Blaise D; Vydra J; Yakoub-Agha I; Choi G; Reményi P; Koc Y; Sanz J; Ciceri F; Mohty M
Bone Marrow Transplant; 2023 May; 58(5):552-557. PubMed ID: 36823454
[TBL] [Abstract][Full Text] [Related]
8. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.
Kanakry CG; Tsai HL; Bolaños-Meade J; Smith BD; Gojo I; Kanakry JA; Kasamon YL; Gladstone DE; Matsui W; Borrello I; Huff CA; Swinnen LJ; Powell JD; Pratz KW; DeZern AE; Showel MM; McDevitt MA; Brodsky RA; Levis MJ; Ambinder RF; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
Blood; 2014 Dec; 124(25):3817-27. PubMed ID: 25316679
[TBL] [Abstract][Full Text] [Related]
9. Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: A Retrospective Cohort Study.
Paul S; Zahurak M; Luznik L; Ambinder RF; Fuchs EJ; Bolaños-Meade J; Wagner-Johnston N; Swinnen LJ; Schoch L; Varadhan R; Jones RJ; Gladstone DE
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1679-1688. PubMed ID: 32592857
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Myeloablative versus Reduced-Intensity Conditioning Regimens in Allogeneic Stem Cell Transplantation Recipients with Acute Myelogenous Leukemia with Measurable Residual Disease-Negative Disease at the Time of Transplantation: A Retrospective Cohort Study.
Yu J; Du Y; Ahmad S; Patel RD; Varela JC; Chang CC; Mori S
Transplant Cell Ther; 2021 Aug; 27(8):663.e1-663.e6. PubMed ID: 33951497
[TBL] [Abstract][Full Text] [Related]
11. Posttransplant cyclophosphamide-based anti-graft-vs-host disease prophylaxis in patients with acute lymphoblastic leukemia treated in complete remission with allogeneic hematopoietic cell transplantation from human leukocyte antigen-mismatched unrelated donors versus haploidentical donors: A study on behalf of the ALWP of the EBMT.
Nagler A; Labopin M; Arat M; Reményi P; Koc Y; Blaise D; Angelucci E; Vydra J; Kulagin A; Socié G; Rovira M; Sica S; Aljurf M; Gülbas Z; Kröger N; Brissot E; Peric Z; Giebel S; Ciceri F; Mohty M
Cancer; 2022 Nov; 128(22):3959-3968. PubMed ID: 36110063
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia.
Dholaria B; Labopin M; Sanz J; Ruggeri A; Cornelissen J; Labussière-Wallet H; Blaise D; Forcade E; Chevallier P; Grassi A; Zubarovskaya L; Kuball J; Ceballos P; Ciceri F; Baron F; Savani BN; Nagler A; Mohty M
J Hematol Oncol; 2021 May; 14(1):76. PubMed ID: 33941226
[TBL] [Abstract][Full Text] [Related]
13. Predictive Factors and Outcomes after Allogeneic Stem Cell Transplantation for Adults with Acute Lymphoblastic Leukemia in Brazil.
Silva WF; Cysne DN; Kerbauy MN; Colturato I; Maia ACA; Tucunduva L; Barros GMN; Colturato VAR; Hamerschlak N; Rocha V
Transplant Cell Ther; 2022 Nov; 28(11):763.e1-763.e7. PubMed ID: 35914726
[TBL] [Abstract][Full Text] [Related]
14. Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.
Rubio MT; Savani BN; Labopin M; Piemontese S; Polge E; Ciceri F; Bacigalupo A; Arcese W; Koc Y; Beelen D; Gülbas Z; Wu D; Santarone S; Tischer J; Afanasyev B; Schmid C; Giebel S; Mohty M; Nagler A
J Hematol Oncol; 2016 Mar; 9():25. PubMed ID: 26980295
[TBL] [Abstract][Full Text] [Related]
15. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
[TBL] [Abstract][Full Text] [Related]
16. Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies.
Law AD; Salas MQ; Lam W; Michelis FV; Thyagu S; Kim DDH; Lipton JH; Kumar R; Messner H; Viswabandya A
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2259-2264. PubMed ID: 30009980
[TBL] [Abstract][Full Text] [Related]
17. Outcome of T-cell-replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Koc Y; Angelucci E; Tischer J; Arat M; Pioltelli P; Bernasconi P; Chiusolo P; Diez-Martin JL; Sanz J; Ciceri F; Peric Z; Giebel S; Canaani J; Mohty M
Cancer; 2021 Jul; 127(14):2507-2514. PubMed ID: 33739471
[TBL] [Abstract][Full Text] [Related]
18. Improved Outcomes of Haploidentical Hematopoietic Cell Transplantation with Total Body Irradiation-Based Myeloablative Conditioning in Acute Lymphoblastic Leukemia.
Dholaria B; Labopin M; Angelucci E; Tischer J; Arat M; Ciceri F; Gülbas Z; Ozdogu H; Sica S; Diez-Martin JL; Koc Y; Pavlu J; Socié G; Giebel S; Savani BN; Nagler A; Mohty M
Transplant Cell Ther; 2021 Feb; 27(2):171.e1-171.e8. PubMed ID: 33830029
[TBL] [Abstract][Full Text] [Related]
19. Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.
Santoro N; Ruggeri A; Labopin M; Bacigalupo A; Ciceri F; Gülbaş Z; Huang H; Afanasyev B; Arcese W; Wu D; Koc Y; Tischer J; Santarone S; Giebel S; Mohty M; Nagler A
J Hematol Oncol; 2017 May; 10(1):113. PubMed ID: 28558762
[TBL] [Abstract][Full Text] [Related]
20. Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation Cyclophosphamide.
Rappazzo KC; Zahurak M; Bettinotti M; Ali SA; Ambinder AJ; Bolaños-Meade J; Borrello I; Dezern AE; Gladstone D; Gocke C; Fuchs E; Huff CA; Imus PH; Jain T; Luznik L; Rahmat L; Swinnen LJ; Wagner-Johnston N; Jones RJ; Ambinder RF
Transplant Cell Ther; 2021 Nov; 27(11):909.e1-909.e6. PubMed ID: 34425261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
